A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
2021 · Blood · 206 citations
https://doi.org/10.1182/blood.2020008936
J
Jianfeng Zhou
Chinese Academy of Medical Sciences & Peking Union Medical College(CN)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
589
Papers
16.6K
Citations
63
h-index
265
i10-index
Jianfeng Zhou is an academic researcher from Chinese Academy of Medical Sciences & Peking Union Medical College. The author has contributed to research in topics: CAR-T cell therapy research & Lymphoma Diagnosis and Treatment & Chronic Lymphocytic Leukemia Research. The author has an h-index of 63, co-authored 501 publications.
ORCID: 0000-0002-1332-9230Papers by this author
worksTreatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
2019 · Leukemia · 153 citations
https://doi.org/10.1038/s41375-019-0545-2
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape
2022 · Signal Transduction and Targeted Therapy · 80 citations
https://doi.org/10.1038/s41392-022-00898-z
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
2022 · Research and Practice in Thrombosis and Haemostasis · 65 citations
https://doi.org/10.1002/rth2.12670
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
2018 · Journal of Hematology & Oncology · 61 citations
https://doi.org/10.1186/s13045-018-0672-7
Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection
2021 · Nature Communications · 60 citations
https://doi.org/10.1038/s41467-021-23621-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat